Associations between metabolic factors and radiographic knee osteoarthritis in early disease - a cross-sectional study of individuals with knee pain

Maria Andersson1,2*, E Haglund1,2,3, K Aili2,4,5, A Bremander1,2,6,7 and S Bergman2,8

Abstract

Objective Metabolic factors have been shown to be associated to severe radiographic knee osteoarthritis (RKOa). However, more knowledge is needed in early clinical knee osteoarthritis (Koa). The aim was to study associations between metabolic factors and radiographic knee osteoarthritis (Oa) in individuals with knee pain. A second aim was to study associations between metabolic factors and RKOa in those with normal BMI and in those overweight/obese, respectively.

Method This cross-sectional study included 282 individuals with knee pain (without cruciate ligament injury) and aged 30–67 years, and 70% women. Waist circumference, body mass index (BMI), proportion of fat and visceral fat area (VFA) were assessed. RKOa was defined as Ahlbäck grade 1 in at least one knee. Fasting blood samples were taken and triglycerides, cholesterol (total, low density lipoprotein (LDL) and high density lipoprotein (HDL)), C-reactive protein (CRP), glucose, HbA1C were analysed. Metabolic syndrome was defined in accordance with the International Diabetes Federation (IDF). Associations were analysed by logistic regression.

Results Individuals with RKOa were older, had higher BMI, higher VFA, larger waist circumference and had increased total cholesterol, triglycerides and LDL-cholesterol, but not fasting glucose. There was no difference between the group with RKOa vs. non-radiographic group regarding the presence of metabolic syndrome. In a subgroup analysis of individuals with normal BMI (n = 126), those with RKOa had higher VFA, more central obesity, higher levels of CRP and total cholesterol, compared with individuals without RKOa. In individuals with obesity, age was the only outcome associated to RKOa.

Conclusion There were clear associations between metabolic factors and RKOa in individuals with knee pain, also in those with normal BMI. In individuals with obesity age was the only variable associated to RKOa.

Trial registration: clinicalTrials.gov Identifier: NCT04928170.

Keywords Knee pain, Knee osteoarthritis, Metabolic factors

*Correspondence: Maria Andersson
maria.andersson@fou-spenshult.se

Full list of author information is available at the end of the article.
Introduction

Osteoarthritis (OA) is a group of diseases with various pathophysiological mechanisms, where metabolic, traumatic and age-related phenotypes seem to be significant [1, 2].

The pathophysiological mechanisms in the metabolic phenotype involve factors that are mainly linked to obesity. Obesity affects the weight-bearing joints through increased load and chronic mechanical stress, which induces chondrocytes by mechanoreceptors to synthesize proinflammatory and cartilage-degrading mediators [3, 4]. However, the increased load is probably not the only factor responsible for the association between obesity and OA. The association between hand OA and obesity cannot be explained by mechanical stress [5, 6]. Associations between knee OA, metabolic syndrome (MetS), diabetes type II, increased lipids, and low-grade inflammation have been reported [7–12]. The common factor in these associations might be adipose tissue. Adipose tissue is an endocrine organ and synthesizes adipokines, which are involved in the regulation of glucose, lipids and inflammatory response, etc. [13, 14]. Adipose tissue forms demarcated areas, such as visceral, subcutaneous, skeletal muscular and bone marrow, with dissimilar cellular compositions and possibly different adipokine secretion [13]. Visceral fat is metabolically active and has been reported to be associated to metabolic diseases, such as diabetes type II and dyslipidaemia, and it increases inflammation [15]. Adipokines may have an impact on the development of OA, by exacerbating inflammation, affecting insulin sensitivity and activating cartilage-degrading mechanisms [16]. Studies have also reported associations between glucose levels and OA in the knee, with possible pathophysiological mechanisms, such as oxidative stress in the chondrocytes and advanced glycation end-product (AGE) formation in the cartilage [10]. Several studies report associations between dyslipidaemia and OA, although the mechanisms are not yet fully known [8, 12].

Most studies of metabolic factors in knee OA (KOA) have been investigated in individuals with severe radiographic knee osteoarthritis RKOA. It is suggested that knee pain should be considered as the first sign of what eventually will become RKOA [17]. The hypothesis for this study is that metabolic factors are increased and associated to RKOA. Studies of individuals with knee pain without radiographic changes, representing the early OA disease process are scarce.

The aim of this cross-sectional study was to investigate associations between metabolic factors and RKOA in individuals with knee pain. A second aim was to study associations between metabolic factors and RKOA in those with normal BMI and in those with obesity, respectively.

Method

Participants

This cross-sectional study present baseline data from an ongoing five-year longitudinal study, the Hallland osteoarthritis cohort (HALLOA), n=306. The HALLOA cohort profile has been published [18]. The inclusion criteria were knee pain, with no former known RKOA, with a preferred age of 30–65 years. The exclusion criteria were any other rheumatological disorder or previous cruciate ligament injury. Enrolment took place from 2017 to 2019, when seeking care for knee pain in primary health care or by advertisements in local newspapers. A general practitioner examined all participants to confirm the exclusion of rheumatological disorder and previous cruciate ligament injury. Individuals with meniscal lesions or tears were not excluded, as meniscal lesions or tears could be a consequence of the OA process [19]. After examination, nine individuals were excluded due to cruciate ligament injury and two individuals were outside the age range. None of the included individuals had clinically detected synovitis at inclusion. In this study, 282 individuals were included after exclusion of 13 individuals who had not been radiographed or not had blood samples taken at baseline. There were no differences in age or sex between those included in the study (n=282) and those not included due to missing radiographs or blood samples (n=13). The study is reported in accordance with the STROBE guidelines.

Outcome measures

Clinical assessments of metabolic factors

Waist circumference was manually assessed with a measuring tape (cm) around the waist, at the height of the navel. Central obesity was classified as waist circumference ≥94 cm in men and ≥80 cm in women [20]. The height and weight were measured, and BMI was presented as continuous data, but also grouped (underweight <18.5 kg/m²; normal 18.5 – 24.9 kg/m²; overweight 25.0 – 29.9 kg/m² and obese ≥30.0 kg/m²). The two groups BMI <25 kg/m² and BMI ≥25 kg/m², representing those under-/ normal weight as well as overweight/obese was also used. Proportion of fat and visceral fat area (VFA) were assessed by Inbody 770 (Biospace South Korea), which has an intercorrelation coefficient of 0.88-1.00, compared to dual-energy x-ray absorptiometry [21, 22]. Raised VFA levels were classified as VFA ≥100cm² [23]. Blood pressure was measured after 5 minutes’ rest (Omron M3, Omron, Sweden). Raised blood pressure was classified as systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg or treatment of previously diagnosed hypertension [20].

Fasting plasma glucose (mmol/L), triglycerides (TG) (mmol/L), total cholesterol (mmol/L), HDL-cholesterol and LDL-cholesterol (mmol/L), HbA1c (mmol/mol) and
C-reactive protein (CRP) > 1.0 mg/L were measured from venous blood, in accordance with the current laboratory standards at Halland County Hospital in Halmstad, Sweden. CRP below 1.0 mg/L was further analysed with a sensitive CRP ELISA method (Abnova). Raised glucose was classified as fasting plasma glucose ≥5.6 mmol/L, or previously diagnosed type II diabetes [20]. Raised triglycerides were classified as triglycerides ≥1.7 mmol/L or specific treatment for this lipid abnormality [20]. Reduced HDL-cholesterol was classified as HDL-cholesterol <1.03 mmol/L in males and 1.29 mmol/L in females, or specific treatment for this lipid abnormality [20]. Metabolic syndrome (MetS) was classified in accordance with the International Diabetes Federation (IDF) definition as central obesity plus any two of the following four factors: raised triglycerides, reduced HDL-cholesterol, raised blood pressure, or raised fasting plasma glucose [20].

Radiographic assessment

The radiographs were obtained in a skyline view of patellofemoral (PF) joints, and posteroanterior radiographs of both tibiofemoral (TF) joints were obtained in weight-bearing position with flexed knees. RKOA was defined in accordance with Ahlbäck [24], i.e. Ahlbäck grade I or more in at least one knee.

Statistics

To test the differences between groups, the Student’s t-test and the chi-squared test were used where appropriate. Spearman’s rank correlation coefficient was used to assess the relationships between continuous variables. The missing data have not been replaced. All missing data are addressed in the tables. The statistical power was estimated with known prevalence of MetS (14–50%) in previous OA studies, which will give a statistical power of 80% for detecting differences at a 5% significance level in this study. The significance tests were two-tailed and conducted at the 0.05 level of significance.

The associations between outcome factors and RKOA were calculated by univariate logistic regression analyses. Variables associated with RKOA with a significance level of p ≤ 0.25 were separately included in a model adjusting for age and sex [25]. Age was adjusted for sex and sex adjusted for age in this model. Cholesterol and LDL-cholesterol were also controlled for lipid-lowering treatment and HbA1c for treatment for diabetes. Analyses of subgroups were performed by selecting individuals with a normal BMI (BMI <25) or obese individuals (BMI ≥25) and comparing those with and without RKOA.

Statistical analyses were performed using SPSS version 21.0 statistical software (IBM Corp., Armonk, NY, USA).

Results

A detailed description of the included individuals is shown in Table 1. Besides knee pain, 22% (n=63) had RKOA at inclusion. About one third fulfilled the criteria for MetS and more than half of the included patients were overweight or obese, and 80% had central obesity. Two thirds had increased blood pressure (whereof 15% were treated for high blood pressure) and more than one third had raised fasting glucose (one individual was treated for diabetes type II). 5% of the included individuals were treated for high lipids.

Radiographic knee osteoarthritis

The group with RKOA (n=63) were on average older, had higher VFA, central obesity, higher total cholesterol and LDL-cholesterol and were more likely to have raised TG, than the group without RKOA. No differences were seen for CRP levels, glucose levels and there was no difference in proportion of MetS between the groups, Table 1.

In a univariate logistic regression, age, BMI, VFA, waist circumference, central obesity, proportion of fat, raised TG and LDL-cholesterol were associated with RKOA, Table 2. In the multivariate logistic regression model, raised VFA and central obesity were associated with having RKOA, Table 2.

Subgroup analysis

Of those with normal BMI (<25 kg/m², n=126), 16% had RKOA, 20% had raised fasting glucose, and 58% had central obesity. Those who had RKOA (n=20) were older, had a higher rate of raised VFA, central obesity and total cholesterol, compared with those who did not fulfil the criteria for RKOA (n=106), Table 3.

In individuals with normal BMI, there were associations between RKOA and older age, higher VFA, central obesity, higher CRP, total cholesterol and LDL-cholesterol, Table 4. In the multivariate logistic regression, raised VFA was associated to RKOA.

In another subgroup analysis of those with overweight/obesity, BMI above 25 kg/m², older age was the only parameter that was associated with RKOA (Tables 5 and 6).

Discussion

This is a study of individuals with knee pain, were also those without radiographic changes, supposedly representing a group with increased probability for being in an early OA disease process [17]. Several metabolic factors were more common in participants with RKOA, also found in individuals with a normal BMI.

There was a high prevalence of individuals with central obesity, increased VFA and overweight/obese (BMI ≥25 kg/m²) in this study group, as was to be expected. Obesity is a risk factor for knee OA [26, 27].
and it is also well known that individuals with knee pain have a high risk of developing RKOA over time, regardless of whether they are overweight or not [17]. A previous study suggests that MetS and its components are causing the knee pain. [28]. However, in this study, only central obesity and VFA were associated with RKOA when adjusting for age and sex, suggesting that visceral fat is an important factor. The impact of visceral fat needs to be studied in a longitudinal setting to be able to study causal relationship. Also, individuals with a normal BMI and RKOA had a higher visceral fat, higher cholesterol levels and higher CRP, compared to those with normal BMI and no radiographic OA. These findings are supported by a newly published study in mice which reported a direct association between adipose tissue and cartilage damage, independent of body weight [29]. For individuals with normal BMI mechanical stress is probably not the main cause of their RKOA, as suggested for obese individuals [30, 31]. Also, in individuals with normal BMI, metabolic factors and visceral fat seem to be more important [32]. Visceral fat measure, such as VFA and central obesity, seems to be more important factors than BMI, when evaluating individuals with knee pain, and risk of having RKOA. BMI does not reflect the body fat mass or amount of visceral fat [33].

In this study, those with RKOA were older, and age is a well-known risk factor for RKOA [34]. When getting older the distribution of visceral fat changes, and if this is causing the increased risk or whether it is the metabolic load over a longer period of time, needs to be elucidated. There was no association between RKOA and sex in this study. A Meta-analysis has found men to have a lower risk of knee OA, especially for those aged 55 and above [35]. However, the criteria for having knee OA differed between the studies included in the meta-analysis, from clinical to radiological with and without symptoms,

Table 1 Description of the included individuals with no radiographic knee OA (no OA), compared to those with radiographic knee OA (RKOA)

|                          | Missing | All | No OA | Mean (sd) | No OA | Mean (sd) | RKOA* | Mean (sd) | p-value |
|--------------------------|---------|-----|-------|-----------|-------|-----------|-------|-----------|---------|
| N                        | 282     | 219 | 63    |           |       |           |       |           |         |
| Age, years               | 0/0     | 52 (8) | 50 (9) | 56 (4) | < 0.001 |           |       |           |         |
| Sex, women, %            | 0/0     | 70 | 70 | 68 | 0.81 |           |       |           |         |
| BMI                      | 0/0     | 26.4 (4.7) | 26.5 (4.8) | 27.8 (4.2) | 0.011 |           |       |           |         |
| BMI < 18.5 kg/m², %      | 0/0     | 1 | 1 | 0 |       |           |       |           |         |
| BMI 18.5–24.9 kg/m², %   | 0/0     | 44 | 47 | 33 | 0.147 |           |       |           |         |
| BMI 25.0–29.9 kg/m², %   | 0/0     | 35 | 33 | 45 |       |           |       |           |         |
| BMI > 30.0 kg/m², %      | 0/0     | 20 | 19 | 22 |       |           |       |           |         |
| Underweight and normal weight, % | 0/0 | 45 | 48 | 32 | 0.019 |           |       |           |         |
| Overweight and obese, %  | 4/1     | 114 (53) | 109 (53) | 128 (51) | 0.014 |           |       |           |         |
| Visceral fat area (VFA)  | 4/1     | 51 | 46 | 68 | 0.003 |           |       |           |         |
| Proportion of fat, %     | 4/1     | 31 (9) | 30 (9) | 33 (9) | 0.042 |           |       |           |         |
| Waist circumference, cm  | 3/1     | 95 (13) | 94 (13) | 99 (12) | 0.011 |           |       |           |         |
| Central obesity, %       | 3/1     | 81 | 76 | 94 | 0.001 |           |       |           |         |
| Raised blood pressure**, % | 1/0 | 63 | 64 | 57 | 0.31 |           |       |           |         |
| CRP, mg/L                | 0/0     | 2.0 (2.6) | 1.9 (2.6) | 2.3 (2.4) | 0.33 |           |       |           |         |
| Total cholesterol, mmol/L| 0/0     | 5.3 (1.1) | 5.2 (1.1) | 5.5 (1.0) | 0.053 |           |       |           |         |
| Triglycerides, mmol/L    | 0/0     | 1.0 (0.6) | 1.0 (0.6) | 1.2 (0.7) | 0.11 |           |       |           |         |
| Raised triglycerides**, %| 0/0     | 12 | 10 | 19 | 0.041 |           |       |           |         |
| LDL-cholesterol, mmol/L  | 0/0     | 3.5 (1.0) | 3.4 (1.0) | 3.7 (1.1) | 0.046 |           |       |           |         |
| HDL-cholesterol, mmol/L  | 0/0     | 1.7 (0.4) | 1.7 (0.4) | 1.7 (0.5) | 0.75 |           |       |           |         |
| Reduced HDL-cholesterol**| 0/0     | 13 | 12 | 14 | 0.69 |           |       |           |         |
| Glucose, mmol/L          | 2/0     | 5.4 (0.8) | 5.4 (0.9) | 5.4 (0.5) | 0.97 |           |       |           |         |
| Raised glucose**, %      | 2/0     | 34 | 35 | 33 | 0.84 |           |       |           |         |
| HbA1c, mmol/mol          | 9/1     | 37 (5) | 37 (5) | 37 (4) | 0.77 |           |       |           |         |
| MetS**, %                | 4/1     | 27 | 26 | 34 | 0.20 |           |       |           |         |

RKOA, radiographic knee osteoarthritis; BMI, body mass index; CRP, C-reactive protein; LDL, LDL, low density lipoprotein; HDL, high density lipoprotein; HbA1C, glycosylated hemoglobin; MetS, metabolic syndrome; KOOS, knee injury and osteoarthritis outcome score; ADL, Function in daily living; Sport/recreation, Function in sport and recreation; QoL, knee-related quality of life

*Ahlbäck grade I or more in at least one knee
**according to International Diabetes Federation (IDF)
which could have affected the results [35]. Another study reported women experiencing more pain regardless of radiographic severity [36], and could fulfil symptom criteria due to more knee pain.

About one fifth of the individuals without RKOA fulfilled the IDF criteria for MetS which is a percentage that is comparable to the general population (22–28%) [37]. One third of those with RKOA fulfilled the criteria for MetS, which is fewer than reported by other studies (43–59%) [7, 38]. An explanation for this disparity between the data in the present study and other studies could be the use of different criteria for MetS. The World Health Organization (WHO) and European Group for the study of Insulin Resistance (EGIR) definitions include insulin resistance in the criteria, whereas the IDF definition has waist circumference as a mandatory component, which could explain the disparity.

About two thirds of the participants had raised blood pressure, with no differences between those with and without RKOA, which is in line with previous studies of individuals with radiological knee OA [7, 39]. In other studies, hypertension or cardiovascular diseases are reported to be linked to OA as elements of the pathological mechanisms in OA [40–42]. One possible explanation between the divergent results could be that our participants were in early disease course and only 22% had RKOA.

One third of the individuals in the present study had raised fasting glucose levels, according to the IDF criteria; however, only one of the included individuals had treatment for diabetes (type II). The cut-off for raised fasting glucose in Sweden is 6.0 mmol/L and the cut-off for raised fasting glucose in the IDF criteria is 5.6 mmol/L, which could explain why most of the participants were untreated for their raised fasting glucose. The mean value of fasting glucose in the present study is in the upper part of the normal range in Sweden (4.0–6.0 mmol/L). In the present study, fasting glucose levels were not associated with RKOA, as reported in other studies [43, 44]. One possible explanation could be that our participants were in early disease course, and few had RKOA.

In the group with normal BMI, those with RKOA had higher level of CRP. CRP was also associated with RKOA in the univariate model and showed a borderline significance in the multivariate logistic regression. The increased inflammation measured by serum CRP is probably caused both by synovial inflammation and inflammation due to obesity [45–48]. The synovial inflammation in OA is already seen in early stages of the disease and increases in later stages [49].

### Table 2

| Table 2 Associations with radiographic knee osteoarthritis (RKOA, Ahlbäck grade I or more in at least one knee) analysed with two logistic regression models. One univariate and one adjusting for age and sex |
|---------------------------------------------------------------|
| **Parameter** | **Univariate logistic regression** | **Adjusting for age and sex** |
| | **OR** | **95% CI** | **p-value** | **OR** | **95% CI** | **p-value** |
| Age, years | 1.13 | 1.07, 1.19 | <0.001 | 1.13 | 1.07, 1.19 | <0.001 |
| Sex, women | 0.93 | 0.51, 1.70 | 0.81 | 0.93 | 0.51, 1.70 | 0.81 |
| BMI | 1.08 | 1.02, 1.14 | 0.013 | 1.06 | 1.00, 1.13 | 0.06 |
| BMI ≥ 25, kg/m² | 2.02 | 1.12, 3.65 | 0.020 | 1.87 | 0.99, 3.52 | 0.05 |
| Visceral fat area (VFA), cm² | 1.01 | 1.00, 1.01 | 0.016 | 1.01 | 1.00, 1.01 | 0.08 |
| Raised VFA (≥ 100), cm² | 2.46 | 1.36, 4.47 | 0.003 | 2.43 | 1.29, 4.55 | 0.006 |
| Proportion of fat, % | 1.03 | 1.00, 1.07 | 0.044 | 1.03 | 0.99, 1.07 | 0.11 |
| Waist circumference, cm | 1.03 | 1.00, 1.05 | 0.012 | 1.02 | 1.00, 1.05 | 0.06 |
| Central obesity* | 6.08 | 1.83, 20.22 | 0.003 | 5.19 | 1.52, 17.72 | 0.009** |
| Raised blood pressure* | 0.74 | 0.42, 1.31 | 0.31 | 0.74 | 0.42, 1.31 | 0.31 |
| CRP, mg/L | 1.05 | 0.95, 1.16 | 0.34 | 1.05 | 0.95, 1.16 | 0.34 |
| Total cholesterol, mmol/L | 1.29 | 1.00, 1.66 | 0.055 | 1.08 | 0.81, 1.43 | 0.61*** |
| Triglycerides, mmol/L | 1.40 | 0.92, 2.14 | 0.12 | 1.19 | 0.75, 1.90 | 0.46*** |
| Raised triglycerides* | 2.21 | 1.02, 4.78 | 0.045 | 1.92 | 0.84, 4.36 | 0.12 |
| LDL-cholesterol, mmol/L | 1.31 | 1.00, 1.71 | 0.048 | 1.12 | 0.84, 1.50 | 0.45*** |
| Reduced HDL-cholesterol* | 1.18 | 0.52, 2.66 | 0.69 | 1.18 | 0.52, 2.66 | 0.69 |
| Glucose, mmol/L | 0.99 | 0.70, 1.40 | 0.97 | 0.99 | 0.70, 1.40 | 0.97 |
| Raised glucose* | 0.94 | 0.52, 1.70 | 0.84 | 0.94 | 0.52, 1.70 | 0.84 |
| HbA1C, mmol/mol | 1.01 | 0.95, 1.07 | 0.77 | 1.01 | 0.95, 1.07 | 0.77 |
| MetS* | 1.49 | 0.81, 2.74 | 0.20 | 1.49 | 0.81, 2.74 | 0.20 |

**BMI, body mass index; CRP, C-reactive protein; LDL, low density lipoprotein; HDL, high density lipoprotein; HbA1C, glycosylated hemoglobin; MetS, metabolic syndrome**

*a according to International Diabetes Federation (IDF) **controlled only for age *** Triglycerides, cholesterol and LDL-cholesterol were also controlled for lipid-lowering treatment
Table 3  Description of the subgroup with normal BMI (n = 126), with and without radiographic knee osteoarthritis (RKO)

| Missing No OA/OA | No OA Mean (sd) | RKO Mean (sd) | p-value |
|------------------|----------------|---------------|---------|
| N                | 166            | 20            |  < 0.001|
| Age, years       | 0/0            | 50 (9)        | 56 (4)  |  < 0.001|
| Sex, women, %    | 0/0            | 78            | 80      | 0.86    |
| Visceral fat area (VFA), cm² | 2/0 | 72 (25) | 89 (30) | 0.008  |
| Raised VFA, (≥ 100 cm²), % | 2/0 | 9 | 40 | < 0.001 |
| Proportion of fat, % | 2/0 | 25 (6) | 27 (8) | 0.11 |
| Waist circumference, cm | 1/1 | 84 (8) | 87 (7) | 0.12 |
| Central obesity, % | 1/1 | 53 | 84 | 0.012 |
| Raised blood pressure**, % | 0/0 | 75 | 55 | 0.08 |
| CRP, mg/L | 0/0 | 1.1 | 2.1 (2.7) | 0.005 |
| Total cholesterol, mmol/L | 0/0 | 4.9 | 5.6 (1.0) | 0.012 |
| Triglycerides, mmol/L | 0/0 | 0.9 | 0.9 (0.5) | 0.82 |
| Raised triglycerides**, % | 0/0 | 3 | 5 | 0.62 |
| LDL-cholesterol, mmol/L | 0/0 | 3.1 | 3.6 (1.2) | 0.06 |
| HDL-cholesterol, mmol/L | 0/0 | 1.8 | 2.0 (0.5) | 0.035 |
| Reduced HDL** | 0/0 | 6 | 5 | 0.90 |
| Glucose, mmol/L | 2/0 | 5.2 | 5.2 (0.4) | 0.72 |
| Raised glucose**, % | 2/0 | 20 | 20 | 0.97 |
| HBA1c, mmol/mol | 3/0 | 36 (3) | 37 (3) | 0.11 |
| MetS**, % | 1/1 | 12 | 16 | 0.68 |

RKO, radiographic knee osteoarthritis; BMI, body mass index; CRP, C-reactive protein; LDL, low density lipoprotein; HDL, high density lipoprotein; HbA1C, glycosylated hemoglobin; MetS, metabolic syndrome

*Ahlbäck grade I or more in at least one knee **according to International Diabetes Federation (IDF)

Lipids were increased in those with RKO in the present study and total cholesterol, LDL-cholesterol and triglyceride levels were associated with RKO. Dyslipidaemia has been reported in previous studies and has been suggested to be involved in the pathogenesis of OA [8, 12, 50].

In individuals with overweight/obesity, 28% had RKO. There were no differences in metabolic factors between the groups with and without RKO. This finding could be explained by the fact that dyslipidaemia and diabetes type II are linked to obesity and both groups were overweight or obese [51, 52]. Because of obesity, the group without radiological knee OA are also at high risk for developing RKO.

One fifth of participants in the present study had RKO, and most had not had a radiographic examination of their knees before study start. The rarity of the studied cohort, still early in the disease course and with a high risk of developing knee OA, will be accentuated in longitudinal follow-up studies.

A limitation in this study was that magnetic resonance imaging (MRI) was not assessed to evaluate the knees, which could have affected the result. The radiographs were scored according to Ahlbäck and not to Kellgren and Lawrence, which is more common. In this study, the aim was to get a cut off for RKO and Ahlbäck grade I is comparable to Kellgren & Lawrence grade II [53]. The use of Ahlbäck grade I or more as cut off for RKO could have affected the result. One of the exclusion criteria was previous cruciate ligament injury diagnosed clinically or by MRI at time for injury; no other knee injuries were included in this exclusion criterion, which also could have influenced the results. Individuals with meniscal lesions or tears were not excluded from the study, which could have influenced the results. Inbody 770 was used instead of DXA, which is the gold standard. This could have influenced the results, however, Inbody 770 has a high correlation to DXA [21] and is a cheaper and easier to use. In the subgroup analyses some of the groups have a small sample size (n = 20 and n = 43), which could have had an impact on the result. However, there were differences in the subgroup analysis and associations were found. All associations found in the subgroup analysis are also found in the whole group. Recruitment in which participants themselves announces interest for enrolment can be a limitation. To minimize this limitation, all participants were examined by a physician at the start of the study. It could although to some extent reduce the generalisability of the results. The number of comparisons in the study increases the risk of rejecting a true null hypothesis, and caution is necessary when interpreting statistical significance. However, this will not alter the interpretation of the main findings. This study is a part of a five-year longitudinal study with yearly interventions, which affords the opportunity to study the disease progress thoroughly.

Conclusion

Metabolic factors were associated with RKO, in this study, also in those with normal BMI. For individuals with normal BMI, increased load and mechanical stress is probably not the main cause of their RKO; instead, metabolic factors could be of importance. The associations between metabolic risk factors and development of RKO in individuals with knee pain, especially in those with normal BMI, needs to be assessed in longitudinal studies, with a focus on pathophysiological mechanisms.
Table 4  Associations with radiographic knee osteoarthritis (RKOA, Ahlbäck grade I or more in at least one knee) in the subgroup with normal BMI (n = 126) analysed with two logistic regression models. One univariate and one adjusting for age and sex

|                          | Univariate logistic regression | Adjusting for age and sex |
|--------------------------|-------------------------------|---------------------------|
|                          | OR  | 95% CI | p-value | OR  | 95% CI | p-value |
| Age, years               | 1.12 | 1.04,1.22 | 0.006 | 1.13 | 1.04, 1.22 | 0.006 |
| Sex, women               | 1.11 | 0.34,3.64 | 0.86 |     |       |         |
| Visceral fat area (VFA), cm² | 1.02 | 1.00,1.04 | 0.017 | 1.02 | 1.01,1.04 | 0.014 |
| Raised VFA (≥ 100), cm²  | 7.04 | 2.28,21.69 | 0.001 | 9.58 | 2.55,35.94 | 0.001 |
| Proportion of fat, %     | 1.06 | 0.99,1.15 | 0.11 | 1.09 | 0.98,1.22 | 0.11 |
| Waist circumference, cm  | 1.04 | 0.99,1.10 | 0.13 | 1.06 | 0.99,1.13 | 0.08 |
| Central obesity*         | 3.50 | 1.10,11.17 | 0.034 | 2.93 | 0.89,9.69 | 0.08 ** |
| Raised blood pressure*   | 0.42 | 0.16,1.12 | 0.08 | 0.51 | 0.18,1.44 | 0.20 |
| CRP, mg/L                | 1.39 | 1.06,1.82 | 0.017 | 1.33 | 0.98,1.82 | 0.07 |
| Total cholesterol, mmol/L | 1.79 | 1.12,2.86 | 0.016 | 1.58 | 0.95,2.63 | 0.08 |
| Triglycerides, mmol/L    | 1.14 | 0.39,3.34 | 0.82 |     |       |         |
| Raised triglycerides*    | 1.79 | 0.18,18.13 | 0.62 |     |       |         |
| LDL-Cholesterol, mmol/L  | 1.61 | 0.98,2.64 | 0.06 | 1.45 | 0.85,2.47 | 0.18 |
| Reduced HDL-Cholesterol mmol/L* | 0.87 | 0.10,7.63 | 0.90 |     |       |         |
| Glucose, mmol/L          | 0.83 | 0.30,2.60 | 0.72 |     |       |         |
| Raised glucose*          | 0.98 | 0.30,3.23 | 0.97 |     |       |         |
| HbA1c, mmol/mol          | 1.13 | 0.97,1.31 | 0.11 | 1.07 | 0.90,1.26 | 0.44 |
| MetS*                    | 1.25 | 0.32,4.86 | 0.75 |     |       |         |

CRP, C-reactive protein; LDL, low density lipoprotein; HDL, high density lipoprotein; HbA1C, glycosylated hemoglobin; MetS, metabolic syndrome

*according to International Diabetes Federation (IDF) **controlled only for age ***. Cholesterol and LDL-cholesterol was also controlled for lipid-lowering treatment and HbA1c for treatment for diabetes
Table 5  Description of the overweight/obese (BMI ≥ 25, n = 156) subgroup, with and without radiographic knee osteoarthritis (RKOA)

|                      | Missing No OA/OA | No OA Mean (sd) | RKOA* Mean(sd) | p-value |
|----------------------|------------------|-----------------|----------------|---------|
| N                    | 113              | 43              |                |         |
| Age, years           |                  | 51 (8)          | 56 (4)         | <0.001  |
| Sex, women, %        |                  | 62              | 63             | 0.92    |
| Visceral fat area (VFA), cm² |                  | 144 (48)        | 147 (49)       | 0.79    |
| Raised VFA, %        |                  | 81              | 81             | 0.99    |
| Proportion of fat, % |                  | 35 (9)          | 35 (8)         | 0.84    |
| Waist circumference, cm |                | 104 (10)        | 104 (10)       | 0.79    |
| Central obesity, %   | 98               | 100             |                | 0.38    |
| Raised blood pressure**, % |            | 54              | 58             | 0.68    |
| CRP, mg/L            | 0/0              | 2.7 (3.3)       | 2.4 (2.4)      | 0.56    |
| Total cholesterol, mmol/L |            | 5.4 (1.1)       | 5.5 (1.0)      | 0.89    |
| Triglycerides, mmol/L |                  | 1.2 (0.7)       | 1.3 (0.7)      | 0.34    |
| Raised triglycerides**, % |            | 16              | 26             | 0.17    |
| LDL, mmol/L          | 0/0              | 3.7 (1.1)       | 3.8 (1.0)      | 0.62    |
| HDL, mmol/L          | 0/0              | 1.6 (0.4)       | 1.5 (0.4)      | 0.24    |
| Reduced HDL**        |                  | 19              | 19             | 0.99    |
| Glucose, mmol/L      | 0/0              | 5.7 (1.1)       | 5.6 (0.6)      | 0.60    |
| Raised glucose**, %  | 48               | 39              |                | 0.36    |
| HBA1c, mmol/mol      | 6/1              | 38 (6)          | 37 (4)         | 0.42    |
| MetS**, %            | 3/0              | 38              | 42             | 0.68    |

RKOA, radiographic knee osteoarthritis; BMI, body mass index; CRP, C-reactive protein; LDL, low density lipoprotein; HDL, high density lipoprotein; HbA1C, glycosylated hemoglobin; MetS, metabolic syndrome

*Ahlbäck grade I or more in at least one knee **according to International Diabetes Federation (IDF)
Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| ADL          | Function in daily living |
| AGE          | Advanced glycation end-product |
| BMI          | Body mass index |
| CRP          | C-reactive protein |
| ELISA        | Enzyme-linked immunosorbent assay |
| IDF          | International Diabetes Federation |
| HALLOA       | The Halland osteoarthritis cohort |
| HbA1C        | Glycosylated hemoglobin |
| LDL          | Low density lipoprotein |
| HDL          | High density lipoprotein |
| HbA1c        | Reduced |
| MetS         | Metabolic syndrome |
| MRI          | Magnetic resonance imaging |
| OA           | Osteoarthritis |
| PF           | Patellofemoral |
| RKOA         | Radiographic knee osteoarthritis |
| TF           | Tibial femoral |
| VFA          | Visceral fat area |

Acknowledgements

The authors thank the participants for taking the time to participate in the study, along with those who help with the examinations. A special thanks to Jan Bagge, who took part in the development and design of the study, as a patient research partner.

Authors’ information

MA is a biomedical scientist and Associate Professor in experimental rheumatology at Lund University, Sweden, with experience in knee OA, rheumatoid arthritis research and as a controller in both OA and rheumatoid arthritis cohorts. EH is a physiotherapist Associate Professor at Halmstad University, Sweden with long clinical experience in rheumatological diseases and research. KA is a physiotherapist PhD, with experience in pain, sleep behaviour, sick leave and mechanical load research. AB is a physiotherapist and Professor in rheumatological rehabilitation, Odense University, Denmark, with long clinical and research experience of rheumatological diseases. SB is MD and Professor in primary health care, University of Gothenburg, Sweden, with a long clinical experience in primary health care and pain research.

Author contributions

All authors contributed equally to the conception and design of the study and interpretation of data, obtained the funding, and read and approved the final version. MA took part in the collection and assembly of data, analysed the data, drafted the article. EH and KA took part in the collection and assembly of data, critically revised the manuscript. AB and SB read it critically for important intellectual content. MA (maria.andersson@fou-spenshult.se) and SB (stefan.bergman@fou-spenshult.se) took responsibility for the integrity of the work, from inception to finished article.

Patient and Public Involvement

A patient research partner, educated in research questions from patient’s perspective, took part in designing the study. The study participants were not involved in the recruitment and conduct of the study. The participants get their own results of blood samples and clinical measurements. The participants will be invited to a lecture presenting the results from this study.

Funding

The study was funded by the Swedish Rheumatism Association, grant number R-531621, R-635431, R-939824, R-967899, Targeted investment from the Swedish Rheumatism Association – Osteoarthritis from 2014 to 2019, and the Crafoord Foundation. The funders have not influenced the study design, collection, analysis, or interpretation of data, nor the writing of the manuscript or the decision to submit the manuscript for publication. Open access funding provided by Lund University.

Data availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Table 6: Associations with radiographic knee osteoarthritis (RKOA), according to Ahlbäck grade I, in the subgroup with overweight/obesity (BMI ≥ 25, n = 156) according to body mass index (BMI). Two models were used, one univariate and one adjusting for age and sex.

| Source of Fat or Blood Measure | Univariate logistic regression | Adjusting for age and sex |
|-------------------------------|-------------------------------|---------------------------|
|                               | OR 95% CI p-value             | OR 95% CI p-value         |
| Age, years                    | 1.14 1.06,1.22 < 0.001        | 1.14 1.06,1.22 < 0.001    |
| Sex, women                    | 1.04 0.50,2.14 0.92           |                           |
| Visceral fat area (VFA), cm²  | 1.00 0.99,1.01 0.79          |                           |
| Raised VFA (≥ 100), cm²       | 0.99 0.40,2.45 0.99          |                           |
| Proportion of fat, %          | 1.00 0.96,1.05 0.84          |                           |
| Waist circumference, cm       | 1.01 0.97,1.04 0.78          |                           |
| Central obesity*              | --                            |                           |
| Raised blood pressure*        | 1.16 0.57,2.36 0.68          |                           |
| CRP, mg/L                     | 0.96 0.84,1.10 0.56          |                           |
| Total cholesterol, mmol/L     | 1.02 0.74,1.41 0.88          |                           |
| Triglycerides, mmol/L         | 1.26 0.78,2.06 0.34          |                           |
| Raised triglycerides*         | 1.81 0.78,4.25 0.17          | 1.55 0.62,3.88 0.35**     |
| LDL-Cholesterol, mmol/L       | 1.09 0.78,1.52 0.62          |                           |
| Reduced HDL-Cholesterol mmol/L*| 1.00 0.41,2.47 0.99          |                           |
| Glucose, mmol/L               | 0.89 0.58,1.37 0.61          |                           |
| Raised glucose*               | 0.71 0.35,1.46 0.36          |                           |
| HbA1c, mmol/mol               | 0.97 0.89,1.05 0.42          |                           |
| MetS*                         | 1.17 0.57,2.39 0.68          |                           |

BMI, body mass index; CRP, C-reactive protein; LDL, low density lipoprotein; HDL, high density lipoprotein; HbA1C, glycosylated hemoglobin; MetS, metabolic syndrome

*according to International Diabetes Federation (IDF) **controlled for age
Declarations

Ethics approval and consent to participate
All participants gave their informed consent to participate in the study, which was obtained in accordance with the Helsinki Declaration [54]. The study was approved by the Regional Ethical Review Board, Faculty of Medicine, University of Lund, Sweden (2016 – 229 and 2017/253).

Consent for publication
N/A.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Clinical Sciences, Rheumatology, Lund University, Lund, Sweden
2Spenshult research and development centre, Halmstad, Sweden
3School of Business, Innovation and Sustainability, Halmstad University, Halmstad, Sweden
4School of Health and Welfare, Halmstad University, Halmstad, Sweden
5Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
6Department of Regional Health Research, University of Southern Denmark, Odense, Denmark
7Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg, Denmark
8School of Public Health and Community Medicine / Primary Health Care, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Received: 12 May 2022 / Accepted: 12 October 2022
Published online: 28 October 2022

References
1. Sellam J, Berenbaum F. Is osteoarthritis a metabolic disease? Joint, bone, spine: revue du rhumatisme. 2013;80:568–73.
2. Berenbaum F, Walker C. Osteoarthritis and inflammation: a serious disease with overlapping phenotypic patterns. Postgrad Med. 2020;132:377–84.
3. Gosser M, Berenbaum F, Levy A, Pignet A, Thirion S, Cavadas S, et al. Mechanical stress and prostaglandin E2 synthesis in cartilage: Biomechanics. 2008;45:293–301.
4. Sturmer T, Gunther KP, Brenner H. Obesity, overweight and patterns of osteoarthritis: the Ulm Osteoarthritis Study. J Clin Epidemiol. 2000;53:307–13.
5. Visser AW, Ioan-Facsinay A, de Muystert R, Widy RA, Loef M, de Roos A, et al. Adiposity and hand osteoarthritis: the Netherlands Epidemiology of Obesity study. Arthritis Res Ther. 2014;16:R19.
6. Yusuf E, Nielsen RG, Ioan-Facsinay A, Stojanovic-Susulic V, DeGroot J, van Osch G, et al. Association between weight or body mass index and hand osteoarthritis: a systematic review. Ann Rheum Dis. 2010;69:761–5.
7. Purenpatom RA, Victor TW. Increased prevalence of metabolic syndrome in individuals with osteoarthritis: an analysis of NHANES III data. Postgrad Med. 2009;121:20–9.
8. Baudart P, Loutat K, Marcelli C, Berenbaum F, Sellam J. Association between osteoarthritis and dyslipidaemia: a systematic literature review and meta-analysis. RMD Open. 2017;3:e000442.
9. Courtes A, Gualillo O, Berenbaum F, Sellam J. Metabolic stress-induced joint inflammation and osteoarthritis. Osteoarthritis and cartilage / OARS. Osteoarthr Res Soc. 2015;23:1955–65.
10. Courtes A, Sellam J. Osteoarthritis and type 2 diabetes mellitus: What are the links? Diabetes research and clinical practice. 2016;128:202–6.
11. Eymard F, Parsons C, Edwards MH, Petit-Dop F, Reginster JY, Bruyere O, et al. Diabetes is a risk factor for knee osteoarthritis progression. Osteoarthritis and cartilage / OARS. Osteoarthritis Research Society. 2015.
12. Famanagh S, Crawford R, Xiao Y, Prasad J. Cholesterol metabolism in pathogenesis of osteoarthritis disease. J Rheum Dis. 2017;20:131–40.
13. Funcke JB, Scherer PE. Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication. J Lipid Res. 2019;60:1648–84.
14. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol. 2010;316:129–39.
15. Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes reviews: official J Int Association Study Obes. 2010;11:1–8.
16. Tu C, Ge J, Wu B, Wang W, Li Z. An extensive review regarding the adipokines in the pathogenesis and progression of osteoarthritis. Cytokine. 2019;113:1–12.
17. Thorsenstson CA, Andersson ML, Jonsson H, Saxne T, Peterson IF. Natural course of knee osteoarthritis in middle-aged subjects with knee pain: 12-year follow-up using clinical and radiographic criteria. Ann Rheum Dis. 2009;68:1890–3.
18. Andersson ML, Haglund E, Alli K, Bremander A, Bergman S. Cohort profile: the Halland osteoarthritis (HALLOA) cohort-from knee pain to osteoarthritis: a longitudinal observational study in Sweden. BMJ open. 2022;12:e057086.
19. Englund M, Guermani A, Lohmander LS. The meniscus in knee osteoarthritis. Rheum Dis Clin North Am. 2009;35:579–90.
20. Alberti KG, Zimmer P, Shaw J. Group IDFETFC. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366:1059–62.
21. Lahay Y, Goldstein N, Gepner Y. Comparison of body composition assessment across body mass index categories by two multifrequency bioelectrical impedance analysis devices and dual-energy X-ray absorptiometry in clinical settings. Eur J Clin Nutr. 2001;213:571–7.
22. Ling CH, de Craen AJ, Slagboom PE, Gunn DA, Stoekel MP, Westendorp RG, et al. Accuracy of direct segmental multi-frequency bioimpedance analysis in the assessment of total body and segmental body composition in middle-aged adult population. Clin Nutr. 2011;30:610–5.
23. Examination Committee of Criteria for ‘Obesity Disease’ in J. Japan Society for the Study of O. New criteria for obesity disease’ in Japan. Circ J. 2002;66:987–92.
24. Ahlback S. Osteoarthrosis of the knee. A radiographic investigation. Acta Radiol Diagn (Stockh.). 1968;Suppl.77:7–72.
25. Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol Med. 2008;3:17.
26. Felson DT, Andersson JI, Naimark A, Walker AM, Meeran RF. Obesity and knee osteoarthritis: The Framingham Study Annals of internal medicine. 1988;109:18–24.
27. Lee R, Kean WF. Obesity and knee osteoarthritis. Inflammopharmacology. 2012;20:53–8.
28. Pan F, Tian J, Cicuttini F, Jones G. Metabolic syndrome and trajectory of knee pain in older adults. Osteoarthritis and cartilage / OARS. Osteoarthritis Research Society. 2020;28:45–52.
29. Collins KH, Lenz KL, Pollitt EN, Ferguson D, Hutson I, Springer LE, et al. Adipose tissue is a critical regulator of osteoarthritis. Proceedings of the National Academy of Sciences of the United States of America. 2021;118.
30. Mobasher A, Carter SD, Martin-Vasallo P, Shababaei M. Integrins and stretch activated ion channels, putative components of functional cell surface mechanoreceptors in articular chondrocytes. Cell Biol Int. 2002;26:1–18.
31. Visser AW, de Mutsert R, le Cesseur S, den Heijer M, Rosendaal FR, Kloppenburg M, et al. The relative contribution of mechanical stress and systemic processes in different types of osteoarthritis: the NEO study. Annals of the rheumatic diseases. 2014.
32. Tatsumi Y, Nakao YM, Masuda I, Higashiyama A, Takegami M, Nishimura K, et al. Risk for metabolic diseases in normal weight individuals with visceral fat accumulation: a cross-sectional study in Japan. BMJ open. 2017;7:e013831.
33. Prentice AM, Jebb SA. Beyond body mass index. Obes reviews: official J Int Association Study Obes. 2001;2:141–7.
34. Petersson IF, Jacobsson LT. Osteoarthritis of the peripheral joints: Best practice & research Clinical Rheumatology. 2002;16:141 – 60.
35. Srikant WR, McKeel DL, Horrier D, Jones G. A meta-analysis of sex differences prevalence, incidence and severity of osteoarthritis. Osteoarthritis and cartilage / OARS. Osteoarthritis Research Society. 2005;13:769 – 81.
36. Glass N, Segal NA, Sluka KA, Torner JC, Nevitt MC, Felson DT, et al. Examining sex differences in knee pain: the multicenter osteoarthritis study. Osteoarthritis and cartilage / OARS. Osteoarthritis Research Society. 2014;22:1100–6.
37. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–9.
38. Momina Hussain S, Wang Y, Cicuttini FM, Simpson JA, Giles GG, Graves S, et al. Incidence of total knee and hip replacement for osteoarthritis in relation to the metabolic syndrome and its components: a prospective cohort study. Semin Arthritis Rheum. 2014;43:429–36.
39. Engstrom G, Gerhardsson de Verdier M, Roloff J, Nilsson PM, Lohmander LS. C-reactive protein, metabolic syndrome and incidence of severe hip and knee osteoarthritis. A population-based cohort study. Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society. 2009;17:168 – 73.
40. Berenbaum F, Sellam J. Obesity and osteoarthritis: what are the links? Joint, bone, spine: revue du rhumatisme. 2008;75:667–8.
41. Conaghan PG, Vanharanta H, Dieppe PA. Is progressive osteoarthritis an atheromatous vascular disease? Ann Rheum Dis. 2005;64:1539–41.
42. Findlay DM. Vascular pathology and osteoarthritis. Rheumatology. 2007;46:1763–8.
43. Schett G, Kleyer A, Perricone C, Sahinbegovic E, Iagnocco A, Zwerina J, et al. Diabetes is an independent predictor for severe osteoarthritis: results from a longitudinal cohort study. Diabetes Care. 2013;36:403–9.
44. Williams MF, London DA, Husni EM, Navaneethan S, Kashyap SR. Type 2 diabetes and osteoarthritis: a systematic review and meta-analysis. J Diabetes Complications. 2016;30:944–50.
45. Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol. 2010;6:625–35.
46. Unamuno X, Gomez-Ambrosi J, Rodriguez A, Becerril S, Frühbeck G, Catalan V. Adipokine dysregulation and adipose tissue inflammation in human obesity. Eur J Clin Invest. 2018;48:e12907.
47. Wenham CY, Conaghan PG. The role of synovitis in osteoarthritis. Ther Adv Musculoskelet Dis. 2010;2:349–59.
48. Goldring MB, Otero M. Inflammation in osteoarthritis. Curr Opin Rheumatol. 2011;23:471–8.
49. Ene R, Sinescu RD, Ene P, Cirstoiu WM, Cirstoiu FC. Synovial inflammation in patients with different stages of knee osteoarthritis. Rom J Morphol Embryol. 2015;56:169–73.
50. Loef M, Schoones JW, Kloppenburg M, Ioan-Facsinay A. Fatty acids and osteoarthritis: different types, different effects. Joint, bone, spine: revue du rhumatisme. 2019;86:451–8.
51. Feingold KR. Dyslipidemia in Diabetes. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, et al., editors. Endotext. South Dartmouth (MA)2000.
52. Feingold KR. Obesity and Dyslipidemia. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, et al., editors. Endotext. South Dartmouth (MA)2000.
53. Petersson IF, Boegard T, Saxne T, Silman AJ, Svensson B. Radiographic osteoarthritis of the knee classified by the Ahlback and Kellgren & Lawrence systems for the tibiofemoral joint in people aged 35–54 years with chronic knee pain. Ann Rheum Dis. 1997;56:493–6.
54. Association WM. WMA Declaration of Helsinki – Ethical principles for medical research involving human subjects. https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/1964.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.